Welcome to our dedicated page for Immatics N.V. SEC filings (Ticker: IMTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Immatics N.V. filings document a foreign private issuer whose regulatory record centers on clinical-stage oncology development, financing capacity and public-company governance. Form 6-K reports furnish press releases, interim reports and investor presentations covering PRAME cell therapy and TCR bispecific programs, including anzu-cel, IMA203CD8, IMA402 and IMA401 MAGEA4/8, along with financial results and business updates.
The filings also include incorporation-by-reference language for Form S-8 and Form F-3 registration statements, leadership and governance disclosures, forward-looking clinical and regulatory risk statements, and capital-structure or shareholder matters tied to the company's Nasdaq-traded security.
Immatics N.V. (IMTX) reported updated early‑stage clinical results for its bispecific TCR candidates and outlined next steps. In Phase 1a, IMA402 (PRAME) treated 80 heavily pre‑treated patients across doses from 0.02–30 mg. A provisional RP2D range of 10–30 mg was identified; the MTD was not reached, and tolerability was favorable with low‑grade CRS (Grade 1 33%, Grade 2 5%, Grade 4 1%), no ICANS and no drug‑related Grade 5 events.
Within the RP2D range, 20 efficacy‑evaluable patients showed a confirmed objective response rate of 30% (6/20), including 29% (4/14) in melanoma. Tumor shrinkage occurred in 55% (11/20) and disease control in 65% (13/20). All six confirmed responses were ongoing at cutoff, with two complete metabolic responses (ongoing at 8 and 18 months).
IMA401 (MAGEA4/8) enrolled 55 patients across 0.0066–2.5 mg, establishing a provisional RP2D of 1–2 mg with low‑grade CRS (24% G1, 11% G2), no ≥Grade 3 CRS and no ICANS; three dose‑limiting events occurred at 2.5 mg. A longest confirmed response exceeded two years. The company is advancing IMA402 to Phase 1b (monotherapy and checkpoint inhibitor combinations) and exploring IMA401+IMA402 combinations in sqNSCLC; it also deprioritized IMA204 and ACTallo.
Immatics N.V. appointed Amie Krause as chief people officer, effective October 27, 2025. Krause brings more than 20 years of experience aligning talent and strategy at global biopharmaceutical companies. She previously held senior HR leadership roles at Dompé, Revance Therapeutics, Atara Biotherapeutics, and spent over a decade at Amgen across multiple regions.
The company issued a press release attached as Exhibit 99.1. This report (excluding Exhibit 99.1) is incorporated by reference into Immatics’ Form S-8 and Form F-3 registration statements.
Immatics N.V. has appointed Venkat Ramanan as its chief financial officer, effective October 1, 2025. He brings more than 25 years of experience in finance, strategy and operations across large and small biopharmaceutical companies.
Ramanan previously served as chief financial officer at Anthos Therapeutics, a clinical-stage biotechnology company acquired by Novartis in April 2025, and at Turnstone Biologics, where he helped lead its initial public offering. He also held senior finance roles at Seagen, Gilead Sciences and Amgen, and holds a Ph.D. in Engineering Mechanics from The Ohio State University. Immatics issued a press release with further details, attached as an exhibit.
Baker Bros. Advisors and affiliated persons report beneficial ownership of 10,168,901 ordinary shares of Immatics N.V., representing 8.4% of the company’s outstanding common stock based on 121,550,169 shares outstanding as reported in the issuer's public filing. The reported holdings are held by two funds (Life Sciences and 667) for which the adviser has sole voting and dispositive power, with 9,354,564 shares held by Life Sciences and 814,337 shares held by 667. This filing amends prior Schedule 13G disclosures and clarifies ownership and control relationships among the adviser, its GP and two individual reporting persons.
This Schedule 13G/A reports that Suvretta Capital Management, LLC and Aaron Cowen each have shared beneficial ownership of 12,030,129 ordinary shares of Immatics N.V., representing 9.9% of the class. Averill Master Fund, Ltd. reports shared beneficial ownership of 10,623,778 shares, representing 8.7% of the class. The filing shows no sole voting or sole dispositive power for any reporting person; all listed voting and dispositive power is shared. The filing states the securities are directly owned by advisory clients of Suvretta, and the reporting persons disclaim beneficial ownership except to the extent of pecuniary interest.
Immatics N.V. submitted a Form 6-K as a foreign private issuer to furnish materials related to its second quarter 2025 reporting. The company issued an interim report covering the three- and six-month period ended June 30, 2025, a press release with second quarter 2025 financial results and a business update, and an updated corporate investor presentation.
The interim report is attached as Exhibit 99.1, the press release as Exhibit 99.2, and the presentation as Exhibit 99.3. The interim report and the core portions of this Form 6-K (excluding the press release and presentation) are incorporated by reference into Immatics’ existing Form S-8 and Form F-3 registration statements, meaning those offering documents now formally include this updated interim information.
Wellington Management and related entities report beneficial ownership of 5,318,624 shares of Immatics N.V. common stock, representing approximately 4.38% of the class. The filing discloses no sole voting or dispositive power; voting is held as shared voting power of 4,545,848 shares and shared dispositive power of 5,318,624 shares. These shares are owned of record by clients of Wellington investment advisers.
The statement clarifies the position is held in the ordinary course of business and not for the purpose of changing or influencing control; no client is identified as having the right to dividends or sale proceeds for more than 5% of the class.